Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Keros Therapeutics ( (KROS) ) is now available.
On January 9, 2026, Keros Therapeutics updated its corporate presentation for investors and analysts, outlining the company’s strategic focus on TGF-β superfamily modulation and highlighting its lead investigational asset, rinvatercept (KER-065), as a modified activin receptor type II ligand trap with potential to improve muscle regeneration, reduce fibrosis and inflammation, decrease fat accumulation and enhance bone health across multiple rare neuromuscular diseases, including Duchenne muscular dystrophy. The presentation underscored the high unmet need in DMD despite existing gene therapies, exon-skipping drugs, glucocorticoids and HDAC inhibitors, and positioned rinvatercept—supported by robust preclinical data showing gains in muscle mass and strength, mitigation of glucocorticoid side effects and improved dystrophic pathology—as a candidate that could broaden Keros’s footprint in neuromuscular and related indications and potentially strengthen its competitive standing in the rare disease biopharma space if its clinical program succeeds.
The most recent analyst rating on (KROS) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Outperform.
Keros Therapeutics receives a strong score due to its positive financial performance and strategic corporate actions. The company’s robust technical indicators and reasonable valuation further support the stock’s attractiveness. However, overbought technical signals and historical financial volatility warrant cautious optimism.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing potentially differentiated product candidates that modulate transforming growth factor-beta (TGF-β) superfamily signaling, targeting pathways critical for the growth, repair and maintenance of multiple tissues and organ systems. Its pipeline includes rinvatercept (KER-065) and elritercept (KER-050) for a range of rare neuromuscular, hematologic and fibrotic conditions, such as Duchenne muscular dystrophy (DMD), myelodysplastic syndromes, myelofibrosis, amyotrophic lateral sclerosis, and obesity/frailty.
Average Trading Volume: 1,036,562
Technical Sentiment Signal: Sell
Current Market Cap: $565.5M
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.